Type 2 Diabetes MellitusNCT07847099
Platelet Indices and Blood Groups in Type 2 Diabetes Vascular Complications
An observational study of Type 2 Diabetes Mellitus and Vascular Complications, run by Assiut University.
Trial summary
This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes Mellitus, Vascular Complications
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 26 Sep 2026to 25 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.
Who may be able to join
- Age 18 years or older
- Confirmed diagnosis of type 2 diabetes mellitus according to ADA criteria
- Written informed consent
Who cannot join
- Type 1 diabetes mellitus
- Gestational diabetes
- Acute infection or sepsis
- Hematological disorders affecting platelet count or function
- Malignancy
- Chronic liver disease
Show all 10Show fewer
- Autoimmune diseases
- Current anticoagulant or antiplatelet therapy
- Recent major surgery or trauma
- Pregnancy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Association of Platelet Indices and Blood Groups With Vascular Complications in Patients With Type 2 Diabetes Mellitus
This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.
Read the detailed description
Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.
This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.
- Conditions
- Type 2 Diabetes Mellitus, Vascular Complications
- Keywords
- Platelet indices, MPV, Type 2 diabetes, ABO blood group, Assiut
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| T2DM with Vascular Complications | Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications. | |
| T2DM without Vascular Complications | Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean platelet volume in patients with and without vascular complications
Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.
Measured: Baseline
Secondary outcomes (5)
Mean platelet distribution width
Mean platelet distribution width (PDW) compared between patients with and without vascular complications.
Measured: Baseline
Distribution of ABO blood groups according to vascular complications
Frequency and percentage of ABO blood groups in patients with and without vascular complications.
Measured: Baseline
Mean platelet volume according to ABO blood group
Mean platelet volume (MPV) among different ABO blood groups.
Measured: Baseline
Prevalence of microvascular complications
Proportion of patients with microvascular complications (retinopathy, nephropathy, or neuropathy).
Measured: Baseline
Prevalence of macrovascular complications
Proportion of patients with macrovascular complications (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2026
- Study start26 Sep 2026 (estimated)
- Primary completion26 Sep 2027 (estimated)
- Study completion25 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nehal Sayed Mohammed Sayed, Assiut University
- Investigators
- Lobna F El-toony, Study chair, Internal Medicine Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07847099
- Sponsor's protocol ID
- Platelet-T2DM-Assiut-2026
- Status last verified
- Sep 2026
- First submitted
- 23 Sep 2026
- Last updated
- 29 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Platelet Indices and Blood Groups With Vascular Complications in Patients With Type 2 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT07847099
- Acronym / sponsor ID
- Platelet-T2DM-Assiut-2026
- Conditions
- Type 2 Diabetes Mellitus, Vascular Complications
- Keywords
- Platelet indices, MPV, Type 2 diabetes, ABO blood group, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 26 Sep 2026 (estimated)
- Primary completion
- 26 Sep 2027 (estimated)
- Study completion
- 25 Mar 2028 (estimated)
- First posted
- 29 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to evaluate the association of platelet indices and ABO blood groups with vascular complications in patients with type 2 diabetes mellitus.
Detailed description
Vascular complications are a major cause of morbidity in type 2 diabetes mellitus. Platelet indices and ABO blood groups may be related to these complications.
This observational study will include adult patients with type 2 diabetes mellitus. Patients will be classified into those with and without vascular complications. Platelet indices (MPV, PDW) and ABO blood groups will be assessed.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| T2DM with Vascular Complications | – | –Patients with type 2 diabetes mellitus who have microvascular or macrovascular complications. |
| T2DM without Vascular Complications | – | –Patients with type 2 diabetes mellitus who have no microvascular or macrovascular complications. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with type 2 diabetes mellitus attending the Internal Medicine Department and Diabetes Center at Assiut University Hospital.
Key inclusion criteria (3 listed)
- Age 18 years or older
- Confirmed diagnosis of type 2 diabetes mellitus according to ADA criteria
- Written informed consent
Key exclusion criteria (10 listed)
- Type 1 diabetes mellitus
- Gestational diabetes
- Acute infection or sepsis
- Hematological disorders affecting platelet count or function
- Malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mean platelet volume in patients with and without vascular complications
Time frame: Baseline
Mean platelet volume (MPV) in femtoliters compared between type 2 diabetes patients with vascular complications and those without vascular complications.
5 secondary outcomes
Mean platelet distribution width
Time frame: Baseline
Distribution of ABO blood groups according to vascular complications
Time frame: Baseline
Mean platelet volume according to ABO blood group
Time frame: Baseline
Prevalence of microvascular complications
Time frame: Baseline
Prevalence of macrovascular complications
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lobna F El-toony study chair
Internal Medicine Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes Mellitus and Vascular Complications, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nehla S Mohamed, Resident (01023327969, Nehal.18313533@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean platelet volume in patients with and without vascular complications (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.